Headquartered in Los Angeles, CA Fiscal year ends December NASDAQ: PBYI pumabiotechnology.com
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. Its primary commercial product is NERLYNX (neratinib), an oral kinase inhibitor approved by the FDA for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, and in combination with capecitabine for the treatment of advanced or metastatic HER2-positive breast cancer patients who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was also granted marketing authorization by the European Commission for extended adjuvant treatment in early-stage hormone receptor-positive HER2-overexpressed/amplified breast cancer. Beyond NERLYNX, Puma in-licensed the development and commercialization rights to alisertib, a selective oral inhibitor of aurora kinase A, which is being developed for the treatment of small cell lung cancer and breast cancer through multiple Phase I/II and Phase II clinical trials under the ALISCA brand. The company operates a patient support program called Puma Patient Lynx to assist with reimbursement and financial assistance for NERLYNX patients. Updated
There’s a small portion of my portfolio I allocate toward companies I’d put in the “higher risk” bucket. For me, that means small caps and companies that trade either under the radar…
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Lee Jackson Tuesday's top analyst upgrades and downgrades included Applied Materials, Aurora Cannabis, Chewy, Coinbase Global, Kinder Morgan, Macy's, Qualcomm and Wells Fargo.
Puma Biotechnology shares made a handy gain early on Thursday after the company presented updated results from its Phase 2 Summit clinical trial of neratinib at the 2019 San Antonio Breast Cancer…
Chris Lange Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Tuesday's top analyst upgrades, downgrades and initiations included Apollo Global Management, BlackRock, Cloudflare, Green Plains, Microsoft, Oracle, Target and TJX Companies.
Puma Biotechnology shares jumped early Wednesday after FDA news about Puma’s breast cancer treatment. However, Puma shares quickly fell off from this FDA sugar high.
Chris Lange Stocks were indicated to open lower on Monday after weekend news that sounds like a China trade deal is not on the way very soon. Investors have been forced to see…
General Electric, Encana Energy, Puma Biotechnology, and Kraft Heinz all posted new 52-week lows Friday.
Stocks were indicated to open higher on China trade deal hopes and after a stronger nonfarm payrolls report. While the stock market has bounced handily from the lows at the end…
Puma Biotechnology shares were climbing on Tuesday after the company announced that it expects a positive outcome in Europe.
Chris Lange The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
The world of biotech can be a rags-to-riches story for companies that build up a drug candidate and secure FDA approval for that drug. And the larger the drug target group is,…
Jon C. Ogg The top analyst upgrades, downgrades and other research calls from Thursday include Albermarle, American Airlines, Ellie Mae, Johnson & Johnson, Mallinckrodt, Mylan, NetApp and Southwest Airlines.
Puma Biotechnology saw its shares take a dive on Wednesday following regulatory events in Europe for its breast cancer treatment.
Chris Lange Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care.
The Wall Street consensus 12-month price target for PBYI is $6.00.
